Product Overview

Product Features

  • Good tolerability [1]
  • Optimum degradation time [2]
  • Excellent necrosis rates [3]
  • Can be combined with other treatment methods [4]
  • Repeatable TACE [5]
  • No particle loading: not limited in the choice of active ingredient for DSM-TACE



Product information and mechanism of action

[1] Niessen et al. (2014): Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of
      hepatocellular carcinoma. J Vasc Interv Radiol 25(2), 240–247; 
[2] Wiggermann et al. (2012): Degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC: Dynamic Contrast-
      Enhanced Ultrasonography (DCE-US) based evaluation of therapeutic efficacy using a novel perfusion software. Clin Hemorheol
      Microcirc 52(2–4), 123–129;
[3] Altomonte et al. (2008): Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.
      Hepatology 48(6), 1864–1873;
[4] Vogl et al. (2014): Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer
      liver metastases: feasibility and survival rates. Eur J Radiol 83(10), 1804–1810; 
[5] Farshid et al. (2013): Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites. Future Oncol
      9(3)´, 419–426

Products EmboCept® S